Interim Review of Safety, Tolerability, and Efficacy From a First-In-Human Phase 1/2a Clinical Study of ICM-203, an Intra-Articular, AAV Gene Therapy for Osteoarthritis

被引：0
|
作者：
Heald, Alison E. [1 ,2 ]
Solomon, Bogdan [3 ]
Page, Richard [4 ,5 ]
Ahn, Yoenhee [1 ]
Yum, Young Na [1 ]
Myung, Jayhyuk [1 ]
Collins, Jamie E. [6 ]
Guermazi, Ali [7 ]
Kim, Dae-Won [1 ,8 ]
机构：
[1] ICM Co LTD, Seoul, South Korea
[2] Univ Washington, Sch Med, Seattle, WA USA
[3] Royal Adelaide Hosp, Adelaide, SA 5000, Australia
[4] Univ Hosp Geelong, Barwon Hlth, Geelong, Vic, Australia
[5] Deakin Univ, Geelong, Vic, Australia
[6] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[7] Boston Univ, Sch Med, Boston, MA 02118 USA
[8] Yonsei Univ, Seoul, South Korea
来源：
MOLECULAR THERAPY | 2024年 / 32卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
146
引用
收藏
页码：80 / 80
页数：1
相关论文
共 42 条
  • [31] First-in-human phase 1/2a study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060+endocrine therapy (ET): Updated safety data in patients with HR+/HER22 mBC
    Giordano, Antonio
    Sharma, Manish
    Williams, Anja
    Schmid, Peter
    Diaz, Diana Fabiola Flores
    Magallanes, Manuel
    Xu, Binghe
    Yan, Min
    Howell, Sacha Jon
    Hamilton, Erika P.
    Basu, Cynthia
    Park, Jennifer
    Neumann, Heather
    Delioukina, Maria
    Yap, Timothy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] The efficacy and safety of RC88 in patients with ovarian cancer, non-squamous-non-small-cell lung-carcinoma and cervical cancer: Results from a first-in-human phase 1/2 study
    Liu, Yutao
    Li, Guiling
    Yang, Runxiang
    Huang, Yu
    Luo, Suxia
    Dang, Qi
    Li, Qingshui
    Huang, Dingzhi
    Huang, Yi
    Tang, Dihong
    Ren, Xiubao
    Zhang, Youzhong
    Zhao, Yuguang
    Liu, Baorui
    Zhou, Jin
    Wang, Yanjie
    Liu, Heping
    Liu, Beisong
    Fang, Jianmin
    Shi, Yuankai
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Phase 1/2 Open-label Dose Evaluation Study of AXO-Lenti-PD Gene Therapy for Parkinson's Disease: Efficacy, Safety, and Tolerability Data from the Second Cohort at 6 Months
    Corcoran, G.
    Karunakara, A.
    Vaughn, B.
    Brand-Schieber, E.
    Foltynie, T.
    Barker, R.
    Palfi, S.
    MOVEMENT DISORDERS, 2021, 36 : S167 - S167
  • [34] Preliminary Results from a First-in-human Phase I/II Gene Therapy Study (FOCUS) of Subretinally Delivered GT005, an Investigational AAV2 Vector, in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration
    Nielsen, Jared
    MacLaren, Robert E.
    Heier, Jeffrey S.
    Steel, David
    Ivanova, Tsveta
    Sivaprasad, Sobha
    Stanga, Paulo
    Bailey, Clare
    Issa, Peter Charbel
    Mendonca, Luisa
    Francis, James
    Curtiss, Darin
    Hughes, Jane
    Waheed, Nadia K.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [35] A phase 1/1b, first-in-human, multi-part study of DF6215, an engineered IL-2Rα-active agonist, to investigate the safety, tolerability, pharmacokinetics, and biological and clinical activity in patients with advanced solid tumors.
    Carneiro, Benedito A.
    McKean, Meredith
    Vicier, Cecile
    Valerin, Jennifer Brooke
    Tarhini, Ahmad A.
    Ganju, Vinod
    Ruisi, Mary M.
    Kirby, Patrick
    Cuillerot, Jean-Marie
    Romano, Emanuela
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] The Guard1 clinical trial - A first in-human, phase 1/2 study evaluating AVR-RD-02, a hematopoietic stem cell (HSC) gene therapy for Gaucher disease: Preliminary safety, pharmacodynamic and clinical efficacy results from the subjects observed for up to 24 months post-infusion
    Adera, Mathews
    Veselinovic, Milena
    Treohan, Anita
    Golipour, Azadeh
    Ridha, Essra
    MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02) : 3 - 4
  • [37] Sustained Efficacy and Safety at Week 52 and Up to Three Years in Adults with Glycogen Storage Disease Type iA (GSDIa): Results from a Phase 1/2 Clinical Trial of DTX401, an AAV8-mediated, Liver-Directed Gene Therapy
    Riba-Wolman, Rebecca
    Rodriguez-Buritica, David F.
    Ahmad, Ayesha
    Pico, Maria-Luz Couce
    Derks, Terry G.
    Mitchell, John
    Weinstein, David A.
    Mitragotri, Deepali
    Valayannopoulos, Vassili
    Crombez, Eric
    MOLECULAR THERAPY, 2022, 30 (04) : 564 - 564
  • [38] Long-Term Efficacy and Safety in Adults with Glycogen Storage Disease Type IA (GSD IA) from a Phase 1/2 Clinical Trial and Long-Term Follow-Up Study of DTX401, an AAV8-Mediated, Liver-Directed Gene Therapy
    Mitchell, John J.
    Riba-Wolman, Rebecca
    Rodriguez-Buritica, David
    Ahmad, Ayesha
    Pico, Maria-Luz Couce
    Derks, Terry G.
    Weinstein, David A.
    Mitragotri, Deepali
    Collis, Richard
    Grimm, Andrew Alexander
    MOLECULAR THERAPY, 2024, 32 (04) : 78 - 79
  • [39] Sustained efficacy and safety up to 3.5 years in adults with glycogen storage disease type Ia (GSDIa): longer-term results from a phase 1/2 clinical trial of DTX401, an AAV8-mediated, liver-directed gene therapy
    Mitchell, J.
    Derks, T. G.
    Riba-Wolman, R.
    Rodriguez-Buritica, D. F.
    Ahmad, A.
    Pico, M. L. Couce
    Weinstein, D. A.
    Mitragotri, D.
    Crombez, E.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A25 - A26
  • [40] A phase Ia/Ib, first-in-human, dose-escalation study evaluating the safety, tolerability, and efficacy of IOS-1002, a LILRB1, LILRB2, and KIR3DL1 targeting HLA-derived fusion protein administered alone or in combination with a PD-1 antibody in patients with advanced solid tumors
    Luen, S. J.
    Ahern, E. S.
    Berger, C.
    Desai, J.
    Frentzas, S.
    Gan, H.
    Gualandi, M.
    Markman, B.
    Millward, M.
    Rafiei, A.
    Tran, B.
    Renner, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S494 - S494
12345